PR90471

GHENT, Belgium, July 6, 2021 /PRNewswire=KYODO JBN/ --

Inbiose, a leading biotech company active in the development of Human Milk

Oligosaccharides (HMOs), is pleased to announce that it has submitted its

application for a Generally Recognized as Safe (GRAS) approval by the US Food &

Drug Administration (FDA) of four HMOs, specifically 6'-Sialyllactose (6'SL),

3-Sialyllactose (3'SL), Lacto-N-Tetraose (LNT) and Lacto-N-neoTetraose (LNnT).

Inbiose will also file for Novel Food approval of these HMOs by the European

Commission (EFSA) in the coming weeks and is preparing a global regulatory

roll-out. Inbiose expects to obtain regulatory approval for these HMOs in 2022

and is currently organizing its industrial production for timely deliveries to

customers in infant nutrition, dietary supplements and functional food and

beverages. Product samples are available for interested parties that wish to

develop innovative products with these HMOs.

"Over the years, Inbiose has earned itself a solid reputation of technological

leadership in the development of HMOs. I am really proud of our team that has

allowed us to take the regulatory step on our way to the market. The approval

of these HMOs in the US and EU will mark the beginning of a whole new range of

advanced HMOs produced by Inbiose" said Prof. Soetaert, CEO and Chairman of

Inbiose.

Inbiose has been developing a wide range of human-identical milk

oligosaccharides that can be industrially produced by sustainable fermentation

processes. Inbiose is currently developing its next generation HMOs that will

permit infant formula to better replicate the composition of breast milk. HMOs

are the newest ingredients for premium infant formula and industry watchers

expect this market to reach Euro 500m by 2025 and grow further to well over

Euro 1bn. The HMO market goes beyond infant nutrition as recent scientific

studies have demonstrated that HMOs may play an important role as bio-active

ingredients for improved immunity, gut health, learning ability and brain

health of the general population.

About Inbiose

Inbiose is a Belgium-based biotech company focused on the research, development

and commercialization of specialty carbohydrates, including human milk

oligosaccharides. Our unique proprietary technology platform "GlycoActives(R)"

enables cost-effective manufacturing of a wide range of specialty carbohydrates

by sustainable fermentation processes.

Photo - https://mma.prnewswire.com/media/1556889/Wim_Soetaert.jpg

Logo - https://mma.prnewswire.com/media/1556149/Inbiose_Logo.jpg

Source: Inbiose